CVRx vs NeuroPace
CVRX and NPCE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVRX and NPCE compare
NeuroPace is the larger company, worth 25 times as much as CVRx ($413M against $16.8M).
NeuroPace grew revenue faster over the last twelve months (23.0% versus 7.8% for CVRx).
NeuroPace keeps more of each dollar of sales as profit, with a net margin of −17.7% compared with −88.3% at CVRx.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVRX | NPCE |
|---|---|---|
| Size and price | ||
| Market cap | $16.8M | $413M |
| Share price | $0.630 | $12.02 |
| Change, 1 year | −93.6% | −10.9% |
| Change, 5 years | −95.2% | 1.4% |
| Beta (5Y) | 1.12 | 1.05 |
| Employees | 223 | 209 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 3.9× |
| P/B | 1.2× (better) | 35.9× |
| FCF yield | −250% | −3.0% (better) |
| Fair value | – | $6.78 |
| Margin of safety | – | −77.2% |
| Growth | ||
| Revenue growth (TTM) | 7.8% | 23.0% (better) |
| Revenue growth, 5Y average | 56.4% (better) | 19.4% |
| Profitability | ||
| Gross margin | 86.9% (better) | 77.8% |
| Operating margin | −81.9% | −9.5% (better) |
| Net margin | −88.3% | −17.7% (better) |
| FCF margin | −69.7% | −11.6% (better) |
| Return on equity | −172% | −126% (better) |
| Return on invested capital | −299% | −41.4% (better) |
| Financial health | ||
| Debt / equity | 4.24 (better) | 5.15 |
| Interest coverage | −8.0× | −1.6× (better) |
| Current ratio | 6.80 (better) | 5.26 |
| Altman Z-score | −10.14 | −3.79 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | −33.8% | 0.00% (better) |
| Shareholder yield | −33.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 57.4% | 77.4% |
| Held by insiders | 49.8% | 16.6% |
| Insider net buying, 12 months | $247K (better) | −$399K |
| Short interest, % of float | 13.6% | 3.0% |
Go deeper
- CVRX stock overview
- CVRX income statement
- CVRX valuation and score
- NPCE stock overview
- NPCE income statement
- NPCE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.